Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: A c-Fos and electrophysiological study

161Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Recent studies have delineated a clear role for the trigeminal innervation of pain-sensitive intracranial structures in the pathophysiology of migraine. The development of new compounds for the treatment of the acute attack of migraine has led to a greater understanding of serotonin (5-hydroxytryptamine; 5HT) receptor diversity. The ergot alkaloids have been used in the treatment of acute attacks of migraine for many years and parenteral administration of dihydroergotamine (DHE) can be a useful treatment strategy. In this study, the question of a possible central site of action of DHE is considered using both anatomical and physiological approaches. The c-Fos method has been used to map functional activation of central neurons in response to stimulation of the superior sagittal sinus (SSS) in the cat. This structure has been used as it refers pain to the ophthalmic division of the trigeminal nerve in humans, and in cats induces changes in neuropeptides and cranial blood flow similar to those seen in migraine. In addition, the temporal aspects of the effect of DHE have been studied by making extracellular recordings from cells in the most caudal aspect of the trigeminal nuclear complex. Stimulation of the SSS results in Fos expression in the superfical laminae of the trigeminal nucleus caudalis and in the dorsal horn of C1 and C2. This activation is blocked by a clinically relevant dose of DHE. Similarly, cells can be recorded in this region that respond to SSS stimulation. This linked cellular activity can be inhibited by the same intravenous dose of DHE. Together, these studies show that DHE can inhibit activity in central trigeminal neurons. Since the sinus and its nerve supply are directly stimulated, the peripheral nerve/vessel innervation is bypassed and this inhibition cannot have happened at any other site. These data imply that drugs acting at the central trigeminal neurons may have a role in the treatment of acute attacks of migraine.

References Powered by Scopus

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

1381Citations
N/AReaders
Get full text

A cytoarchitectonic atlas of the spinal coed in the cat

984Citations
N/AReaders
Get full text

Treatment of Migraine Attacks with Sumatriptan: The Subcutaneous Sumatriptan International Study Group

555Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The induction of pain: An integrative review

1479Citations
N/AReaders
Get full text

Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons

520Citations
N/AReaders
Get full text

Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater

375Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Hoskin, K. L., Kaube, H., & Goadsby, P. J. (1996). Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: A c-Fos and electrophysiological study. Brain, 119(1), 249–256. https://doi.org/10.1093/brain/119.1.249

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

52%

Researcher 6

29%

Professor / Associate Prof. 4

19%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 6

33%

Medicine and Dentistry 6

33%

Neuroscience 4

22%

Pharmacology, Toxicology and Pharmaceut... 2

11%

Save time finding and organizing research with Mendeley

Sign up for free